

2023 CAMO ANNUAL SCIENTIFIC MEETING

FINAL PROGRAM

EMERGING NOVEL SYSTEMIC THERAPIES – WHO IS IN CHARGE?

Thursday, April 27, 2023 | MaRS Centre in Toronto, ON



Dr. Stephanie Snow (Halifax, NS) 2023 ASM Co-Chair



Dr. Zachary Veitch (Barrie, ON) 2023 ASM Co-Chair



Email: info@camo-acom.ca Tel: 613.415.6033 Website: www.camo-acom.ca



CAMO 2023 ANNUAL SCIENTIFIC MEETING

Overall Objectives

- 1. Identify ways oncologists can advocate for the Canadian Cancer Care system.
- 2. Describe various emerging novel systemic therapies in solid tumors.
- 3. Discuss how novel therapies are implemented into cancer care systems across Canada.
- 4. Establish and promote a network of medical oncology colleagues from both community and academic settings.

Scientific Planning Committee (SPC)

Co-Chairs

Dr. Stephanie Snow, QEII Health Sciences Centre, Halifax, NS

Dr. Zachary Veitch, Royal Victoria Hospital, Barrie, ON

CPD Representative

Dr. Ghazaleh Kazemi, Juravinski Regional Cancer Centre, Hamilton, ON

Committee Members

Dr. Sharlene Gill, BC Cancer, Vancouver, BC

Dr. Desiree Hao, Tom Baker Cancer Centre, Calgary, AB

Dr. Erin Powell, Dr. H. Bliss Murphy Cancer Centre, St. Johns, NL

Dr. Stephen Welch, London Regional Cancer Program, London, ON

Abstract Judges

Dr. Richard Lee-Ying, Tom Baker Cancer Centre, Calgary, AB

Dr. Jacques Raphael, London Regional Cancer Program, London, ON

Dr. Erica Tsang, Princess Margaret Cancer Centre, Toronto, ON

Dr. Ravi Ramjeesingh, Nova Scotia Cancer Centre, Halifax, NS

Use #CAMO23 when you tweet to participate in conversations & share what you're learning with colleagues



Please visit the Virtual Poster Hall that is open to all meeting attendees.

Simply scan the QR Code





CAMO 2023 Annual Scientific Meeting

Thursday, April 27, 2023 | MaRS Centre - Auditorium

07h05 - 07h15 Welcome remarks from CAMO President - Dr. Sharlene Gill

07h15 – 08h15 Sponsored Breakfast Symposium

08h15 – 10h15 CAMO Oral Presentations (12 presentations)

Objectives (7-minute presentation, followed by 3-minute Q&A) At the end of the session, participants will be able to:

- 1. Describe recent research findings in the field of Medical Oncology.
- 2. Describe interesting cases in the field of Medical Oncology.
- 0815-0825: MAINSTREAM MODEL OF GENETIC TESTING FOR PROSTATE CANCER: THE SUNNYBROOK ODETTE CANCER CENTRE EXPERIENCE | Xin (Kevin) Wang, University of Toronto
- 0825-0835: DOES COMMUNITY SIZE IMPACT SURVIVAL WITH BREAST CANCER? DATA FROM A LARGE POPULATION-BASED COHORT IN BRITISH COLUMBIA | Emily Jackson, University of British Columbia
- 0835-0845: OUTCOMES OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS TREATED IN THE LENVATINIB (LEN) AND IMMUNOTHERAPY ERA (2018-2021) COMPARED TO THE SORAFENIB (SOR) ERA (2008-2018) | Chloe Lim, University of Calgary
- 0845-0855: A COMPREHENSIVE FRAMEWORK FOR ASSESSING AND IMPROVING WELLNESS IN THE MEDICAL ONCOLOGY TRAINING PROGRAM AT THE UNIVERSITY OF OTTAWA | Julian Surujballi, University of Ottawa
- 0855-0905: BENEFIT OF ADJUVANT BISPHOSPHONATES IN EARLY BREAST CANCER TREATED WITH CONTEMPORARY SYSTEMIC THERAPY: A META-ANALYSIS OF RANDOMIZED CONTROL TRIALS | Abhenil Mittal, University of Toronto
- 0905-0915: RATES OF SURGERY AND ADJUVANT CHEMOTHERAPY USE IN STAGE IB-IIIA NON-SMALL CELL LUNG CANCER PATIENTS: AN ONTARIO POPULATION-BASED STUDY | Yuchen Li, McMaster University
- 0915-0925: THE IMPACT OF COVID-19 ON THE WELLNESS AND RESILIENCE OF THE CANADIAN MEDICAL ONCOLOGY WORKFORCE: A CANADIAN ASSOCIATION OF MEDICAL ONCOLOGISTS SURVEY | Lauren Jones, University of British Columbia
- 0925-0935: A RETROSPECTIVE REVIEW OF PRIMARY PROPHYLAXIS WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) FOR PATIENTS WITH GENITOURINARY MALIGNANCIES RECEIVING CHEMOTHERAPY DURING THE COVID-19 PANDEMIC AND IMPLICATIONS FOR THE FUTURE | Nely Diaz Mejia, University of Toronto
- 0935-0945: REAL-WORLD EVALUATION OF BONE TARGETED AGENTS AND FIRST BONE RADIATION INCIDENCE IN PROSTATE CANCER DECEDENTS: A PROVINCIAL-WIDE POPULATION STUDY | William Phillips, University of Ottawa
- 0945-0955 : ANEMIA IS INVERSELY ASSOCIATED WITH PATIENT SURVIVAL IN MELANOMA PATIENTS TREATED WITH IMMUNOTHERAPY | Hyejee Ohm, University of Alberta
- 0955-1005 : ANDROGEN RECEPTOR IS EXPRESSED IN THE MAJORITY OF BREAST CANCER BRAIN METASTASES AND IS SUBTYPE-DEPENDENT | Kevin Yijun Fan, University of Toronto
- 1005-1015: INFORMATIVE TOOLS TO OPTIMIZE NEOADJUVANT THERAPY IN ER POSITIVE, HER2 NEGATIVE BREAST CANCERS | Lidiya Luzhna, University of British Columbia

10h15 – 11h00 Poster Viewing/Judging and Networking Break



CAMO 2023 Annual Scientific Meeting

Thursday, April 27, 2023 | MaRS Centre - Auditorium

11h00 – 12h00 CAMO Keynote Speaker * CLAIM SECTION 3 CREDITS

Physicians as Advocates: What can the Medical Oncologist Community do to Advance Timely and Equitable Cancer Care Access in Canada?

Dr. Paul Wheatley-Price (Ottawa, ON)

Objectives (45-minute presentation followed by 15-minute Q&A)

At the end of the session, participants will be able to:

- 1. Have a better understanding of the regulatory system in Canada.
- 2. Have a better understanding of different roles medical oncologists can play in advocating within the system.

12h15 - 13h30 CAMO Annual General Meeting & Lunch (members only) (Room: Auditorium)

12h15 – 13h30 Lunch for Delegates (not attending AGM) (Room: CR-3)

13h45 - 14h00 Sponsor Recognition, Fellowship Presentation & Best Resident Abstracts

Dr. Sharlene Gill - CAMO President

Dr. David Dawe - Chair, Fellowship Commitee

Dr. Stephanie Snow & Dr. Zachary Veitch – Co-Chairs, Annual Scientific Meeting Committee

14h00 - 17h00 CAMO Symposium: Emerging Novel Systemic Therapies - Who is in Charge?

14h00 – 14h25 Emerging Adoptive Cell Therapy Strategies in Solid Tumors – Dr. Adrian Sacher (Toronto, ON)

Objectives (25-minute presentation followed by 7-minute Q&A)

At the end of the session, participants will be able to:

- 1. Review current promising approaches to adoptive cell therapy in solid tumors.
- 2. Evaluate evolving evidence for promising cell therapy strategies.
- 3. Discuss potential challenges and toxicities associated with novel cell therapy strategies.

14h32 – 14h57 Bispecifics/BiTE: What a Medical Oncologist Needs to Know – Dr. Maryam Soleimani (Vancouver, BC)

Objectives (25-minute presentation followed by 7-minute Q&A)

At the end of the session, participants will be able to:

- 1. Discuss what bispecifics and BiTEs are and their mechanism of action.
- 2. Evaluate potential solid malignancies applicable to these therapies.
- 3. Evaluate the unique toxicity profile of these drugs and their management.

15h04 - 15h29 Theranostics: Lu-177 PRRT & PSMA-RLT - Dr. Jean-Mathieu Beauregard (Québec City, QC)

Objectives (25-minute presentation followed by 7-minute Q&A)

At the end of the session, participants will be able to:

- 1. Describe the principles of theranostics.
- 2. List the indications of PRRT and PSMA-RLT.
- 3. Appraise their potential benefits and toxicities.

15h40 – 15h50 Poster Viewing and Networking Break

15h50 – 16h50 Panel Discussion

Drs. Mita Manna (Saskatoon, SK) Robyn Macfarlane (Halifax, NS) Adrian Sacher (Toronto, ON)

Maryam Soleimani (Vancouver, BC) Jean-Mathieu Beauregard (Québec City, QC)

Objectives (45-minute discussion followed by 15-minute Q&A)

At the end of the session, participants will be able to:

- 1. Understand the pan-Canadian perspective on implementing novel therapies
- 2. Understand their impact to institutional work flows and how they can be successfully integrated for academic or regional/community centers among other insights



CAMO 2023 Annual Scientific Meeting

Thursday, April 27, 2023 | Ontario Heritage Centre

10 Adelaide Street East, Toronto | *Pre-registration required – no onsite tickets

18h30-19h00 CAMO Awards Gala Welcome Reception

19h00 – 22h00 Pioneer Lecture Series

From Pre-Med to Emeritus Professor: A Personal History (I'm More Surprised Than Anyone To Be Standing Here) – Dr. Peter Venner (Edmonton, AB)

Objectives (35-minute discussion + 10-minute Q&A)

At the end of the session, participants will be able to:

1. See how easy it is to apply the abilities you have acquired to be a competent medical oncologist (CanMeds in a Nutshell).

CAMO Annual Achievement Awards presented by

Dr. Stephen Welch, Chair Membership Committee & Dr. Sharlene Gill, CAMO President

CAMO Pioneer Award Recipient

Dr. Peter Venner (Edmonton, AB)

CAMO Rising Star Award Finalists

Dr. Katarzyna Jerzak (Toronto, ON)

Dr. Aly-Khan Lalani (Hamilton, ON)

CAMO Distinguished Service Award Finalists

Dr. Charles Butts (Edmonton, AB)

Dr. Philip Champion (Charlettetown, PEI)

Dr. Scott Ernst (London, ON)

Dr. Natasha Leighl (Toronto, ON)

Dr. Scott North (Edmonton, AB)

CAMO Volunteer of the Year Award

To be announced...



This event is an Accredited Group Learning Activity (**Section 1**) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Association of Medical Oncologists. **You may claim a maximum of 5.75 hours** (credits are automatically calculated).

This activity is an Accredited Self-Assessment Program (**Section 3**) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Association of Medical Oncologists. **You may claim a maximum of 1 hour** (credits are automatically calculated).







THANK YOU!

Please visit the sponsor showcase to learn more about each company and to connect one-on-one with representatives



DIAMOND LEVEL





GOLD LEVEL













SILVER LEVEL









BRONZE LEVEL



















BEST RESIDENT ABSTRACT

